Treatment
|
Frequency of application |
Design
of study
& duration of treatment |
n
|
Proportion
(%) of subjects with
treatment-related adverse events |
Specific
treatment-related adverse events and proportion (%) affected
|
Proportion (%) withdrawn due to treatment-related adverse events |
Trial
|
|
Desonide
lotion 0.05% |
tid |
C, D-B, R; 3 wk |
30 |
3.3 (5.0) |
Stinging:
3.3 (5.0) |
0 (10) |
Greenspan,
1993 |
|
Clobetasol
propionate 0.05% cream |
tid |
C, D-B, R, M; 2 wk |
57 |
3.5 |
Burning:
3.5 Skin
atrophy: 0 |
0 |
Jegasothy,
1985 |
|
Betamethasone
valerate cream 0.1% |
bid |
C, D-B, R; 4 wk |
179 |
4.0 |
Pruritus:
1.0 Burning:
2.0 Psoriasis
exacerbation: 0.5 Folliculitis: 0.5 |
0 |
Callen,
1996 |
|
Fluticasone
propionate cream 0.05% |
bid |
C, D-B, R; 4 wk |
171 |
4.5 |
Pruritus:
3.0 Burning:
0.5 Dryness:
1.0 |
0 |
Callen,
1996 |
|
Tacalcitol
ointment (4 íg/g) |
qd |
C, R, M; 8 wk |
42 |
4.8 |
Irritation: 2.4 Erythema: 2.4 Pigmentation: 0 |
** |
Farkas,
1999 |
|
Calcitriol
ointment (3
íg/g) |
bid |
C, R 8 wk |
60 |
5.0 |
Skin irritation: 5.0 |
0 |
Hutchinson,
2000 |
|
Fluocinonide
cream 0.05% |
tid |
C, D-B, R, M; 2 wk |
57 |
5.3 |
Burning:
5.3 Skin
atrophy: 0 |
0 |
Jegasothy,
1985 |
|
Betamethasone dipropionate
cream 0.05%
(augmented) |
qd |
C, R, M; 2 wk |
123 |
5.7 |
Pruritus:
1.6 Stinging:
0.8 Dermatitis:
0.8 Viral
infection: 0.8 URI:
0.8 |
0 |
Ellis,
1989 |
|
Fluticasone
propionate ointment 0.005% |
bid |
CT, D-B, R, M; 4 wk |
193 |
6.7 (6.3) |
Burning
and/or pruritus : 6.0 (6.0) Hypertrichosis:
0.5 |
0 (0) |
Olsen,
1996 |
|
Desonide
cream 0.05% |
tid |
C, D-B, R; 3 wk |
30 |
6.7 |
Stinging:
3.3 Erythema:
3.3 |
0 |
Greenspan,
1993 |
|
Fluocinonide
ointment 0.05% |
bid |
C, D-B, R, M; 6 wk |
57 |
7.1 |
Pruritus:
1.8 Stinging:
1.8 Psoriasis
exacerbation: 3.6 Acne:
1.8 |
1.8 |
Bruce,
1994 |
|
Fluocinonide
cream 0.05% |
bid |
C,
R, M; 12
wk |
113 |
9.0 |
Pruritus:
1 Burning:
7 Erythema:
1 |
2 |
Lebwohl,
1998 |
|
Fluocinonide
cream 0.05% |
bid |
C, R, M; 2 wk |
121 |
9.1 |
Pruritus:
2.5 Stinging:
0.8 Pain:
0.8 Application site rxn: 0.8 Headache:
0.8 Fever:
0.8 Viral
infection: 1.7 URI:
0.8 Follicular
rash: 0.8 |
2.5 |
Ellis,
1989 |
|
Calcipotriene*
ointment 0.005% |
bid |
C, D-B, R; 4 wk |
63 |
9.5 |
Lesional
pruritus/burning: 9.5 |
1.6 |
Salmhofer,
2000 |
|
Mometasone
furoate 0.1% ointment |
bid |
C, D-B, R,M; 3 wk |
205 |
10 |
Application
site reaction: 8 Skin
atrophy: 2.4 |
1.0 |
Koo,
1998 |
|
Betamethasone
valerate ointment (1 mg/g) |
bid |
C, D-B, R, M; 6 wk |
204 |
10.3 |
Lesional/perilesional
irritation: 3.9 Irritation
of face/scalp: 0.0 Erythema/desquamation: 1.5 Skin
infection: 2.5 Misc.
skin problems: 1.0 Nondermatologic:
1.5 |
1.5 |
Cunliffe,
1992 |
|
Calcipotriene* ointment (50 íg/g) |
bid |
C, D-B, R, M; 8 wk |
145 |
11.7 |
Pruritus: 1.4 Rash: 7.6 |
3.4 |
Veien,
1997 |
|
Mometasone
furoate 0.1%/salicylic acid 5% ointment |
bid |
C, D-B, R,M; 3 wk |
203 |
12 |
Application site reaction: 9 Skin
atrophy: 3.0 |
0.5 |
Koo,
1998 |
|
Calcipotriene*
ointment (CP) 0.005% / Diflucortolone valerate ointment 0.1% (DV) |
CP: q am DV: q pm |
C, D-B, R; 4 wk |
63 |
12.7 |
Lesional
pruritus/burning: 12.7 |
0 |
Salmhofer,
2000 |
|
Tacalcitol
ointment (4 íg/g) |
qd |
C, D-B, R, M; 8 wk |
142 |
12.7 |
Pruritus: 7.0 Rash: 7.7 |
2.8 |
Veien,
1997 |
|
Mometasone
furoate 0.1% ointment |
bid |
C, D-B, R, M; 3 wk |
135 |
13 |
Pruritus:
<1.0% Burning:
1.0 Skin
atrophy: <1.0% |
0 |
Katz,
1998 |
|
Tazarotene
gel 0.05% |
qd |
C, D-B, R,M; 8 wk |
52 |
13 |
Pruritus/ Burning/ Erythema |
3.8 |
Krueger,
1998 |
|
Calcipotriene*
cream (CP) (50 íg/g) / Betamethasone 17- valerate cream (BM) (1 mg/g) |
CP: q am BM: q pm |
CT, D-B, R, M; 8 wk |
175 |
17.1 |
Lesional/
perilesional irritation: 22.9 |
1.7 |
Kragballe,
1998 |
|
Calcipotriene
ointment 0.005% |
bid |
C, D-B, R, M; 6 wk |
56 |
17.5 |
Pruritus:
7.0 Burning:
8.8 Erythema:
1.8 Rash:
1.8 Contact
dermatitis: 1.8 |
0 |
Bruce,
1994 |
|
Coal
tar (5%)/ allantoin (2%)/ hydrocortisone (0.5%) cream |
bid |
C, R, M; 8 wk |
57 |
17.5 |
Pruritus/irritation/burning:
8.8 Erythema: 0 Soreness: 1.8 Rash: 1.8 Psoriasis exacerbation: 1.8 |
5.3 |
Pinheiro,
1997 |
|
Salicylic
acid 5% |
bid |
C, D-B, R, M; 3 wk |
67 |
18 |
Pruritus/
Burning Skin
atrophy: 0 |
0 |
Katz,
1998 |
|
Mometasone
furoate 0.1%/salicylic acid 5% ointment |
bid |
C, D-B, R, M; 3 wk |
133 |
20 |
Pruritus:
4.0 Burning:
5.0 Skin
atrophy: 8.3 |
0 |
Katz,
1998 |
|
Calcipotriene
ointment 0.005% |
bid |
CT, D-B, R, M; 8 wk |
139 |
20.1 (15.2) |
Rash:
10.8 (3.6) Pruritus:
2.2 (2.9) Burning:
2.2 Erythema:
2.9 (Psoriasis exacerbation: 4.3) |
4.3 (5.8) |
Highton,
1995 |
|
Hydrocortisone
buteprate 0.1% cream |
bid |
CT, D-B, R, M; 3 wk |
94 |
23 |
Headache:
7.0 URI:
2.0 |
0 |
Sears,
1997 |
|
Calcipotriene*
ointment (50 íg/g) |
bid |
C, R, M; 8 wk |
65 |
23.1 |
Pruritus/irritation/burning:
12.3 Erythema: 6.2 Soreness: 1.5 Rash: 0 Psoriasis exacerbation: 1.5 |
1.5 |
Pinheiro,
1997 |
|
Calcipotriene*
cream (CP) (50 ug/g) / Clobetasone 17- Butyrate
cream (CB) (0.5 mg/g) |
CP: q am CB: q pm |
CT, D-B, R, M; 8 wk |
172 |
23.8 |
Lesional/
perilesional irritation: 29.0 |
1.7 |
Kragballe,
1998 |
|
Calcipotriene*
cream, suspended (50 íg/g) |
bid |
CT,
D-B, R, M; 8 wk |
161 |
26.1 |
Lesional/perilesional
irritation: 10.6 Psoriasis exacerbation: 1.9 Misc.
skin problems: 6.8 Nondermatologic:
4.3 |
1.2 |
Harrington,
1996 |
|
Calcipotriene*
cream, dissolved (50 íg/g) |
bid |
CT,
D-B, R, M; 8 wk |
165 |
27.3 |
Lesional/perilesional
irritation: 15.2 Psoriasis
exacerbation: 0.6 Misc.
skin problems: 4.8 Nondermatologic:
0.6 |
3.6 |
Harrington,
1996 |
|
Tazarotene
gel 0.05% |
qd |
C, R,M; 12 wk |